VENBIO GLOBAL STRATEGIC FUND II, L.P. - MENLO THERAPEUTICS INC. -- SCHEDULE 13D

Company

VYNE Therapeutics Inc.

Filed

February 8, 2018

Accession Number

0001072613-18-000093

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →